NXTC Director Gets 18,700-Share Option at $0.47 – Routine Form 4

NextCure, Inc. (NXTC) – Form 4 insider filing On 24 June 2025, director Ellen Feigal filed a Form 4 reporting the grant of a stock option on 20 June 2025.

Rhea-AI Filing Summary

NextCure, Inc. (NXTC) – Form 4 insider filing

On 24 June 2025, director Ellen Feigal filed a Form 4 reporting the grant of a stock option on 20 June 2025. The option covers 18,700 shares of common stock at an exercise price of $0.47 per share. It vests in full on the earlier of 20 June 2026 or the date of NextCure’s 2026 Annual Meeting of Stockholders and carries an expiration date of 19 June 2035. Ownership is reported as direct.

No open-market purchases or sales of common shares were disclosed, and no additional derivative or non-derivative transactions were listed. After the grant, Dr. Feigal’s beneficial ownership consists solely of these 18,700 option shares.

The filing represents a routine equity incentive award to a director and does not convey new operational or financial performance data.

Insights

Financial Analyst

TL;DR: Routine director option grant; neutral impact on valuation or near-term stock performance.

The Form 4 shows a standard incentive option for 18,700 shares at $0.47. No cash transactions occurred, and the strike aligns roughly with recent market prices, indicating a routine annual award rather than an opportunistic trade. The size is immaterial relative to NextCure’s float, so dilution risk is negligible. Because no insider buying or selling signal is present, and no operational information accompanies the filing, investors should view the disclosure as administratively neutral.

Insider Trade Summary

Grant/Award: 18,700 shares

Grant/Award 1 txn

Insider Feigal Ellen

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	18,700	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 18,700 contracts (Direct)

Footnotes (1)

1. F1. The option vests in full on the earlier of June 20, 2026 and the date of the 2026 Annual Meeting of Stockholders.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the NXTC Form 4 dated June 24 2025 disclose?

A director received an option to purchase 18,700 common shares at $0.47 per share.

Who is the reporting insider in the June 2025 Form 4 for NextCure?

Director Ellen Feigal is the reporting person.

How many shares are covered by the new stock option granted to Ellen Feigal?

The option covers 18,700 shares of NextCure common stock.

When do the newly granted NXTC options vest and expire?

They vest on the earlier of 20 June 2026 or the 2026 Annual Meeting and expire on 19 June 2035.

Did the Form 4 show any open-market purchase or sale of NXTC shares?

No. Only an option grant was reported; no shares were bought or sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2025 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feigal Ellen

(Last) (First) (Middle)

C/O NEXTCURE, INC.

9000 VIRGINIA MANOR ROAD, SUITE 200

(Street)

BELTSVILLE MD 20705

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NextCure, Inc. [ NXTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.47	06/20/2025		A		18,700		(1)	06/19/2035	Common Stock	18,700	$0	18,700	D

Explanation of Responses:

1. The option vests in full on the earlier of June 20, 2026 and the date of the 2026 Annual Meeting of Stockholders.

	/s/ Steven P. Cobourn, as attorney-in-fact for Ellen Feigal	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.